Biosimilars stocks
바이오시밀러
What are Biosimilars stocks in Korea?
The Biosimilars theme on jonbur groups 13 Korean stocks listed on KOSPI and KOSDAQ, worth ₩143T in total. On Oct 30, 2026 the group moved up 4.19% (weighted by market value); the largest members are Samsung Biologics, Celltrion, Alteogen.
Key facts
- Stocks
- 13
- Total market value
- ₩143T
- Day's move
- +4.19%
- As of
- Oct 30, 2026
- Largest members
- Samsung Biologics, Celltrion, Alteogen
Earnings tracker · 2Q 2025
Past quarter
Combined, for the companies that have reported, vs the same quarter a year ago
| Company | Reported | Revenue | vs a year ago | Operating profit | vs a year ago | vs last quarter | Op. margin |
|---|---|---|---|---|---|---|---|
| Samsung Biologics | Aug 14 | ₩1.3T | +11.5% | ₩476B | +9.5% | −2.3% | 36.9%37.6% |
| Celltrion | Aug 14 | ₩961B | +9.9% | ₩242B | +234.5% | +62.3% | 25.2%8.3% |
| Alteogen | Aug 13 | ₩19B | +52.4% | −₩426M | Smaller loss | Turned to loss | −2.3%−55.0% |
| SAM Chun Dang Pharm | Aug 14 | ₩57B | +3.7% | −₩1.1B | Turned to loss | Turned to loss | −1.9%3.9% |
| Celltrion Pharm | Aug 14 | ₩131B | +12.1% | ₩16B | +64.8% | +44.6% | 11.8%8.0% |
| Komipharm International | Aug 13 | ₩14B | −28.6% | ₩1.6B | −58.9% | +219.5% | 11.9%20.6% |
| Prestige BioPharma | Sep 19 | ₩5.4M | +140.6% | −₩13M | Smaller loss | Smaller loss | −242.4%−684.9% |
| ISU Abxis | Aug 14 | ₩23B | +59.2% | ₩9.4B | +96.8% | Turned to profit | 41.1%33.2% |
| Prestige Biologics | Sep 19 | ₩8.9B | +194.5% | −₩9.7B | Smaller loss | Smaller loss | −109.5%−427.2% |
| CKD Bio | Aug 14 | ₩41B | −19.1% | ₩2.9B | −42.3% | +37.8% | 7.0%9.8% |
| Aprogen Biologics | Aug 13 | ₩15B | −1.9% | −₩18B | Bigger loss | Bigger loss | −120.5%−79.9% |
| Samsung Epis Holdings | Not yet | ||||||
| IMBiologics | Not yet | ||||||
Single-quarter figures. Preliminary figures are the company's own early numbers and are replaced by the quarterly report when it's filed. Expected dates are around when each company reported a year ago.
Technical breadth
After the close on Oct 30, 2026- Above 20-day average
- 15.4%
- Above 60-day average
- 23.1%
- RSI above 70
- 0%
- RSI below 30
- 23.1%
- 52-week highs
- 0
- 52-week lows
- 2
Index gauge · Short term
Bearish
0 bullish, 2 neutral, 7 bearish
Index gauge · Medium term
Bearish
0 bullish, 1 neutral, 7 bearish
Technical read
The Biosimilars theme covers 9 Korean stocks, and only 22.2% of them are trading above both their 20-day and 60-day averages. The group has no names at 52-week highs or lows, and its RSI extreme count shows one member near oversold territory at 22.2 with none overbought. The equal-weighted member index sits below its cloud with an RSI of 35.2, and its short- and medium-term signals both read bearish, with 7 of 9 members on the bearish side in each window.
Written by AI from the indicator values above. Not advice.
Share of members, from each member's own indicators; the gauge reads an equal-weighted index of the members. Technical indicators describe past price and volume patterns. They are not predictions or recommendations.
Credit & macro
- MaturitiesOct 23, 202685ISU Abxis: ₩50bn of bonds due in the next 6 months vs ₩23bn cash₩50bn due within 12 months, from the bond filings so far; cash and cash equivalents as of 2026 H1.ISU Abxis
ETFs for this theme
All ETFs →AUM · Flow 1w
Biosimilars
−0.67%바이오시밀러
Biosimilars are copies of biologic drugs, which are complex medicines made from living cells, that are shown to be highly similar to an already-approved reference product in quality, safety, and efficacy. Korean investors group the theme together because several domestic companies, including Samsung Biologics, Celltrion, and Hanmi-linked developers, have built large manufacturing or development capabilities in this area. Because the sector sits at the intersection of pharmaceuticals, contract manufacturing, and patent-expiry timelines, the theme is often discussed as a single category even though individual companies differ in business models.
13 companies · 4 up · 0 flat · 9 down
- Traded value
- ₩345B
- Value vs 20-day average
- 1.03×
- Top gainer
- Samsung Biologics +8.86%
- Largest company
- Samsung Biologics ₩69T
Companies in this theme
| Company | Price | Daily | Traded value | Market cap | NPS |
|---|---|---|---|---|---|
Samsung Biologics207940 · KOSPI | ₩1,487,000 | +8.86% | ₩144B | ₩69T | 6.88% |
Celltrion068270 · KOSPI | ₩191,600 | +1.22% | ₩100B | ₩44T | 7.28% |
Alteogen196170 · KOSDAQ | ₩211,500 | −3.86% | ₩71B | ₩15T | 2.68% |
Samsung Epis Holdings0126Z0 · KOSPI | ₩309,500 | +0.81% | ₩8.9B | ₩7.7T | 5.70% |
SAM Chun Dang Pharm000250 · KOSDAQ | ₩182,700 | −3.13% | ₩15B | ₩4.3T | 1.34% |
Celltrion Pharm068760 · KOSDAQ | ₩36,650 | −0.41% | ₩1.4B | ₩1.6T | 0.49% |
Komipharm International041960 · KOSDAQ | ₩9,070 | +3.66% | ₩2.2B | ₩677B | 0.02% |
Prestige BioPharma950210 · KOSPI | ₩4,020 | −3.25% | ₩349M | ₩242B | 0.15% |
IMBiologics493280 · KOSDAQ | ₩13,160 | −4.64% | ₩1.6B | ₩195B | — |
ISU Abxis086890 · KOSDAQ | ₩3,435 | −1.58% | ₩201M | ₩140B | 0.20% |
Prestige Biologics334970 · KOSDAQ | ₩1,158 | −2.93% | ₩226M | ₩90B | — |
CKD Bio063160 · KOSPI | ₩12,330 | −0.16% | ₩47M | ₩68B | 0.62% |
Aprogen Biologics003060 · KOSPI | ₩1,335 | −3.26% | ₩125M | ₩40B | 0.08% |
Source: KRX statistical information